Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Save to My Library
Look up keyword or section
Like this
3Activity

Table Of Contents

1. BACKGROUND
1.2.1Indicators of progression
1.2.2 CONCLUSIONS
1.2.3REFERENCES
2.RISK FACTORS
3.ASSESSMENT
3.1 Symptom scores
3.1.1International Prostate Symptom Score (I-PSS)
3.1.2 Quality-of-life assessment
3.1.3Symptom score as decision tool for treatment
3.1.4Symptom score as outcome predictor
3.1.5Conclusions
3.1.6 RECOMMENDATIONS
3.2 Prostate-specific antigen (PSA) measurement
3.2.1 Factors influencing the serum levels of PSA
3.2.2 PSA and prediction of prostatic volume
3.2.3 PSA and probability of having prostate cancer
3.2.4 PSA and prediction of BPH-related outcomes
3.2.5 Conclusions
3.2.6 RECOMMENDATION
3.2.7 REFERENCES
3.3 Creatinine measurement
3.3.2 REFERENCES
3.4 Urinalysis
3.4.1RECOMMENDATION
3.5 Digital rectal examination (DRE)
3.5.3 CONCLUSIONS AND RECOMMENDATION
3.5.4. REFERENCES
3.6 Imaging of the urinary tract
3.6.1 Upper urinary tract
3.6.2 Lower urinary tract
3.6.3 Urethra
3.6.4 Prostate
3.6.5 REFERENCES
3.7 Voiding charts (diaries)
3.7.1CONCLUSIONS
3.7.2REFERENCES
3.8 Uroflowmetry
3.8.1REFERENCES
3.9 Post-void residual volume
3.10Urodynamic studies
3.10.1Outcome
3.10.2CONCLUSIONS
3.10.3REFERENCES
3.11Endoscopy
3.11.1LUTS caused by bladder outlet obstruction
3.11.2Morbidity of urethrocystoscopy
3.11.3Relationship between trabeculation and peak flow rate
3.11.4Relationship between trabeculation and symptoms
3.11.5Relationship between trabeculation and prostate size
3.11.6Relationship between trabeculation and obstruction
3.11.7Bladder diverticula and obstruction
3.11.8Bladder stones and obstruction
3.11.9Intravesical pathology
3.11.11REFERENCES
3.12 RECOMMENDATIONS FOR ASSESSMENT
4.TREATMENT
4.1.1Patient selection
4.1.2 Education, reassurance and periodic monitoring
4.1.3Lifestyle advice
4.1.5REFERENCES
4.2 Medical treatment
4.2.15-alpha reductase inhibitors
4.2.1.1Finasteride (type 2, 5-alpha reductase inhibitor)
4.2.1.1.1Efficacy and clinical endpoints
4.2.1.1.2 Haematuria and finasteride
4.2.1.1.3Side-effects
4.2.1.1.4Effect on PSA
4.2.1.3 Combination therapy
4.2.1.4CONCLUSIONS
4.2.1.5 REFERENCES
4.2.2Alpha-blockers
4.2.2.1Uroselectivity
4.2.2.2Mechanism of action
4.2.2.3Pharmacokinetics
4.2.2.4Assessment
4.2.2.5Clinical efficacy
4.2.2.6Durability
4.2.2.7Adverse effects
4.2.2.8Acute urinary retention
4.2.2.9CONCLUSIONS
4.2.2.10REFERENCES
4.2.3 Phytotherapeutic agents
4.2.3.1CONCLUSIONS
4.2.3.2REFERENCES
4.3 Surgical management
4.3.1 Indications for surgery
4.3.3 Perioperative antibiotics
4.3.4 Treatment outcome
4.3.5 Complications
4.3.6 Long-term outcome
4.3.7 CONCLUSIONS AND RECOMMENDATIONS
4.3.8 REFERENCES
4.4 Lasers
4.4.1Laser types
4.4.2 Right-angle fibres
4.4.4Holmium laser resection of the prostate (HoLRP)
4.4.5CONCLUSIONS
4.4.6REFERENCES
4.5 Transrectal high-intensity focused ultrasound (HIFU)
0 of .
Results for:
No results containing your search query
P. 1
11 BPH

11 BPH

Ratings: (0)|Views: 187 |Likes:
Published by Badrul Hisham

More info:

Published by: Badrul Hisham on Jul 30, 2011
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

01/31/2013

pdf

text

original

You're Reading a Free Preview
Pages 6 to 59 are not shown in this preview.

Activity (3)

You've already reviewed this. Edit your review.
1 thousand reads
1 hundred reads
christyxjade liked this

You're Reading a Free Preview

Download
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->